These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 16202789

  • 1. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB, Comeau AM.
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [Abstract] [Full Text] [Related]

  • 2. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ.
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [Abstract] [Full Text] [Related]

  • 3. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM.
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [Abstract] [Full Text] [Related]

  • 4. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C, ECFS CF Neonatal Screening Working Group.
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [Abstract] [Full Text] [Related]

  • 5. Sweat testing infants detected by cystic fibrosis newborn screening.
    Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP.
    J Pediatr; 2005 Sep; 147(3 Suppl):S69-72. PubMed ID: 16202787
    [Abstract] [Full Text] [Related]

  • 6. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB.
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [Abstract] [Full Text] [Related]

  • 7. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
    Sermet-Gaudelus I, Roussel D, Bui S, Deneuville E, Huet F, Reix P, Bellon G, Lenoir G, Edelman A.
    BMC Pediatr; 2006 Oct 03; 6():25. PubMed ID: 17018149
    [Abstract] [Full Text] [Related]

  • 8. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
    Massie RJ, Wilcken B, Van Asperen P, Dorney S, Gruca M, Wiley V, Gaskin K.
    J Pediatr; 2000 Aug 03; 137(2):214-20. PubMed ID: 10931414
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
    Ren CL, Desai H, Platt M, Dixon M.
    Pediatr Pulmonol; 2011 Nov 03; 46(11):1079-84. PubMed ID: 21538969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.
    Sermet-Gaudelus I, Girodon E, Roussel D, Deneuville E, Bui S, Huet F, Guillot M, Aboutaam R, Renouil M, Munck A, des Georges M, Iron A, Thauvin-Robinet C, Fajac I, Lenoir G, Roussey M, Edelman A.
    Thorax; 2010 Jun 03; 65(6):539-44. PubMed ID: 20522854
    [Abstract] [Full Text] [Related]

  • 15. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.
    Keiles S, Koepke R, Parad R, Kharrazi M, California Cystic Fibrosis Newborn Screening Consortium.
    J Cyst Fibros; 2012 May 03; 11(3):257-60. PubMed ID: 22209734
    [Abstract] [Full Text] [Related]

  • 16. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, Kulozik AE, Mall MA, Hoffmann GF.
    J Inherit Metab Dis; 2010 Oct 03; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J, Curnow L, Tzanakos N, Francis I, Robertson CF.
    Arch Dis Child; 2006 Mar 03; 91(3):222-5. PubMed ID: 16243854
    [Abstract] [Full Text] [Related]

  • 19. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
    Sontag MK, Corey M, Hokanson JE, Marshall JA, Sommer SS, Zerbe GO, Accurso FJ.
    J Pediatr; 2006 Nov 03; 149(5):650-657. PubMed ID: 17095337
    [Abstract] [Full Text] [Related]

  • 20. [Neonatal screening for cystic fibrosis].
    Tellería Orriols JJ, Alonso Ramos MJ, Garrote Adrados JA, Fernández Carvajal I, Blanco Quirós A.
    An Esp Pediatr; 2002 Jul 03; 57(1):60-5. PubMed ID: 12139895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.